Selective sigma-2 ligands preferentially bind to pancreatic adenocarcinomas: applications in diagnostic imaging and therapy
2007

Selective sigma-2 ligands and pancreatic cancer

publication Evidence: moderate

Author Information

Author(s): Kashiwagi Hiroyuki, McDunn Jonathan E, Simon Peter O Jr, Goedegebuure Peter S, Xu Jinbin, Jones Lynne, Chang Katherine, Johnston Fabian, Trinkaus Kathryn, Hotchkiss Richard S, Mach Robert H, Hawkins William G

Primary Institution: Washington University School of Medicine

Hypothesis

Can sigma-2 receptor ligands induce apoptosis in pancreatic cancer cells?

Conclusion

The study demonstrates that sigma-2 receptor ligands can significantly increase pancreatic cancer cell death and may serve as a new therapeutic target.

Supporting Evidence

  • The sigma-2 receptor was found to be over-expressed in pancreatic cancer cell lines.
  • Sigma-2 receptor ligands induced apoptosis in pancreatic cancer cells in a dose-dependent manner.
  • Micro-PET imaging showed preferential binding of sigma-2 ligands to tumors compared to normal tissues.
  • A single dose of WC26 caused approximately 50% apoptosis in tumors.
  • Treatment with WC26 significantly slowed tumor growth in animal models.

Takeaway

This study found that certain molecules can help kill pancreatic cancer cells, which is important because this type of cancer is very hard to treat.

Methodology

The study used in vitro and in vivo experiments to assess the binding and apoptosis-inducing effects of sigma-2 receptor ligands on pancreatic cancer cells.

Limitations

The study primarily focused on specific cancer cell lines and animal models, which may not fully represent human pancreatic cancer.

Statistical Information

P-Value

p < 0.0001

Statistical Significance

p < 0.0001

Digital Object Identifier (DOI)

10.1186/1476-4598-6-48

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication